ASMB vs. OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry.
Assembly Biosciences vs. Its Competitors
Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.
Omeros presently has a consensus price target of $18.00, indicating a potential upside of 290.46%. Assembly Biosciences has a consensus price target of $41.25, indicating a potential upside of 68.50%. Given Omeros' higher possible upside, research analysts plainly believe Omeros is more favorable than Assembly Biosciences.
48.8% of Omeros shares are owned by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 5.3% of Assembly Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Omeros has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
In the previous week, Omeros had 1 more articles in the media than Assembly Biosciences. MarketBeat recorded 2 mentions for Omeros and 1 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.44 beat Assembly Biosciences' score of 0.37 indicating that Omeros is being referred to more favorably in the media.
Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -117.20%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.
Summary
Omeros beats Assembly Biosciences on 11 of the 15 factors compared between the two stocks.
Get Assembly Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Assembly Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:ASMB) was last updated on 10/6/2025 by MarketBeat.com Staff
